The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Secukinumab Effective for Treating Psoriatic Arthritis

Secukinumab Effective for Treating Psoriatic Arthritis

July 15, 2015 • By Reuters Staff

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters Health)—The anti-interleukin-17A monoclonal antibody secukinumab improves signs and symptoms in patients with psoriatic arthritis, according to results from Novartis’ FUTURE 2 trial.

You Might Also Like
  • Secukinumab Effective for Psoriatic Arthritis
  • Phase 3 Trials: Secukinumab for Psoriatic Arthritis & DA-DKP for OA
  • Psoriatic Arthritis Patients Show Long-Term, Sustained Improvement with Secukinumab

In earlier studies, secukinumab has demonstrated superior effectiveness to placebo and etanercept in improving the signs and symptoms of psoriasis.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Iain B. McInnes from the University of Glasgow in the U.K. and colleagues investigated the efficacy and safety of secukinumab versus placebo in 397 patients with psoriatic arthritis at 76 centers in Asia, Australia, Europe and North America.

At week 24, ACR20 responses were significantly higher with secukinumab 300 mg (54%), 150 mg (51%) and 75 mg (29%) than with placebo (15%), the team reports in The Lancet, online June 29.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The 300-mg and 150-mg doses of secukinumab also brought significantly increased PASI75 and PASI90 rates, along with improvements in DAS28-CRP and quality of life, compared with placebo.

Clinical responses with the two higher doses of secukinumab were maintained through 52 weeks of treatment in patients initially allocated to these treatments.

Adverse events were similar across treatment groups except for a slightly higher incidence of serious adverse events in the secukinumab 300-mg and 75-mg groups than in the secukinumab 150-mg and placebo groups.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

“These data provide further evidence that interleukin 17A is an important cytokine in the pathogenesis of psoriatic arthritis, and suggest that secukinumab, by providing an alternative mechanism of action to current treatments, might be a useful future treatment option,” the researchers conclude.

“Although no direct comparison can be made, it does seem that secukinumab provides an equivalent improvement in the musculoskeletal manifestations to that seen in previous TNF-alpha inhibitor studies,” write Dr. Philip Helliwell and Dr. Laura Coates from the University of Leeds, U.K., in a related editorial.

“However, no evidence exists to guide the sequencing of drugs or which therapies are best for subgroups of patients, such as those with asymmetrical oligoarthritis or predominant enthesitis or axial disease,” they conclude.

“From the current perspective, it seems likely that interleukin-17 inhibitors will be used after failure of, or intolerance to, a TNF inhibitor. However, because of the availability of other biological agents, such as interleukin 12/23 inhibitors, and targeted synthetic drugs, such as apremilast, just how these drugs should be used for optimum management of patients with psoriatic arthritis is a key research question,” they add.

The European Commission and the U.S. Food and Drug Administration approved secukinumab for the treatment of moderate to severe plaque psoriasis in January 2015. The drug is also approved in Australia.

Pages: 1 2 | Single Page

Filed Under: Biologics & Biosimilars, Conditions, Drug Updates, Systemic Inflammatory Syndromes Tagged With: Biologics & Biosimilars, Interleukin, Psoriatic Arthritis, secukinumab

You Might Also Like:
  • Secukinumab Effective for Psoriatic Arthritis
  • Phase 3 Trials: Secukinumab for Psoriatic Arthritis & DA-DKP for OA
  • Psoriatic Arthritis Patients Show Long-Term, Sustained Improvement with Secukinumab
  • Apremilast Effective for Psoriatic Arthritis

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.